Ocular Therapeutix, Inc. (OCUL) is a publicly traded Healthcare sector company. As of May 21, 2026, OCUL trades at $8.04 with a market cap of $1.83B and a P/E ratio of -5.63. OCUL moved +0.38% today. Year to date, OCUL is -30.48%; over the trailing twelve months it is +5.66%. Its 52-week range spans $5.79 to $16.44. Analyst consensus is strong buy with an average price target of $24.50. Rallies surfaces OCUL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who is trading OCUL stock inside the company?
Recent OCUL insider activity includes Dugel Pravin sold 20.06K, Kaiser Peter sold 2.81K, Heier Jeffrey S. sold 3.06K, Nayak Sanjay sold 1.76K, and Waheed Nadia sold 3.51K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
OCUL Key Metrics
Key financial metrics for OCUL
Metric
Value
Price
$8.04
Market Cap
$1.83B
P/E Ratio
-5.63
EPS
$-1.44
Dividend Yield
0.00%
52-Week High
$16.44
52-Week Low
$5.79
Volume
6.69K
Avg Volume
0
Revenue (TTM)
$52.04M
Net Income
$-290.50M
Gross Margin
87.24%
Recent OCUL Insider Trades
Dugel Pravin sold 20.06K (~$166.06K) on Feb 23, 2026.
Kaiser Peter sold 2.81K (~$23.27K) on Feb 23, 2026.
Heier Jeffrey S. sold 3.06K (~$25.31K) on Feb 23, 2026.
Nayak Sanjay sold 1.76K (~$14.56K) on Feb 23, 2026.
Waheed Nadia sold 3.51K (~$27.17K) on Feb 20, 2026.
Recent OCUL insider activity includes Dugel Pravin sold 20.06K, Kaiser Peter sold 2.81K, Heier Jeffrey S. sold 3.06K, Nayak Sanjay sold 1.76K, and Waheed Nadia sold 3.51K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for OCUL?
Yes. Rallies tracks OCUL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is OCUL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for OCUL. It does not provide personalized investment advice.
